Since the prostate cancer-prevalent T:E fusion gene is formed by the fusion with the androgen-responsive regulatory region of the AR-targeted TMPRSS2 gene, it is generally viewed that T:E fusion is primarily regulated by AR and its aberrant expression in androgen-dependent prostate cancer is mainly attributed to the activated AR signaling, and AR targeting by androgen ablation or hormone therapy could help to suppress its aberrant overexpression in prostate cancer. Here, TMPRSS2 is linked to prostate carcinoma.